US · Healthcare · Medical Devices
EPS came in at 1.42 against a street estimate of 1.43 — a miss of 0.7%.
Analysts rate Abbott Laboratories a buy (23 buy, 5 hold, 0 sell out of 28) with an average price target of $118.52.
CONFIDENT Abbott reported 7% third-quarter sales growth and 9% EPS growth, while announcing a tax-free Nutrition spin-off expected by end-2027. Medical Devices and Diagnostics were strong; near-term guidance implies continued acceleration. Q3 FY26 Management highlighted strong U.S., European, Japanese, and Latin American Diagnostics performance, plus double-digit EPD growth in several emerging markets. Analysts focused on the Nutrition separation, litigation liabilities, guidance, pipeline launches, Diagnostics momentum, and future M&A. Management emphasized strategic focus, strong capitalization, and temporary business-specific headwinds. 2026-10-21…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.82% |
| Vanguard Capital Management, LLC | 6.57% |
| State Street Corp | 4.68% |
| Charles Schwab Investment Management Inc | 3.45% |
| Vanguard Portfolio Management, LLC | 2.83% |
| Geode Capital Management, LLC | 2.27% |
| Capital Research Global Investors | 2.13% |
| Capital Research & Mgmt Co - Division 3 | 2.00% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $13,013 million, up from $11,369 million in the third quarter of 2025. • Nine-month 2026 net sa | 2026-11-04 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Abbott Laboratories filed a Form 8-K on October 21, 2026. • Abbott announced plans to separate its global nutrition business into | 2026-10-21 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 reported sales rose 14.5% to $13.013 billion; comparable sales increased 7.0%. • GAAP diluted EPS was $0.53, d | 2026-10-21 |
| Reg FD disclosure · Q3 2026 ABBOTT LABORATORIES (ABT) - 8-K FILING SUMMARY HEADLINE NUMBERS • Settlement amount: approximately $670 million to resolve Gill lawsuit plus ~2,000 | 2026-08-20 |
| Quarterly report · Q2 2026 ABBOTT LABORATORIES – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q2 2026: $12,593 million (up 13% vs Q2 2025: $11,142 million) • Net sales H1 | 2026-07-28 |
| Results announced · Q3 2026 ABBOTT LABORATORIES Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 reported sales growth: 13.0% ($12.593 billion) • Q2 2026 comparable sales gro | 2026-07-16 |
| Quarterly report · Q1 2026 ABBOTT LABORATORIES Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $11,164 million vs. $10,358 million in Q1 2025 (up 7.8%) • Net earnin | 2026-04-29 |
| Board / officer change · Q2 2026 ABBOTT LABORATORIES (ABT) – FORM 8-K SUMMARY April 24, 2026 Annual Shareholder Meeting --- BUSINESS & SEGMENT HIGHLIGHTS • Kevin Conroy appointed t | 2026-04-27 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.63 / share ex-date Oct 15, 2026 · pay Nov 16, 2026 | 2026-10-15 |
| Dividend | $0.63 / share ex-date Jul 15, 2026 · pay Aug 17, 2026 | 2026-07-15 |
| Dividend | $0.63 / share ex-date Apr 15, 2026 · pay May 15, 2026 | 2026-04-15 |
| Dividend | $0.63 / share ex-date Jan 15, 2026 · pay Feb 13, 2026 | 2026-01-15 |
| Dividend | $0.59 / share ex-date Oct 15, 2025 · pay Nov 17, 2025 | 2025-10-15 |
| Announcement | Date |
|---|---|
| Completed acquisition of Exact Sciences Corporation for $105 per share Abbott Laboratories completed its acquisition of Exact Sciences Corporation on March 23, 2026. Under the merger agreement signed in November 2025, Exact Sciences shareholders received $105 p | 2026-03-23 |
| Completed $20B debt offering to fund Exact Sciences acquisition Abbott Laboratories successfully raised $20 billion through a public bond offering on March 9, 2026. The company issued eight series of notes with varying maturity dates (2029-2066) and inte | 2026-03-09 |
| Agrees to acquire Exact Sciences for $105 per share in cash Abbott Laboratories agreed to acquire Exact Sciences Corporation for $105 per share in an all-cash transaction announced November 20, 2025. Abbott will pay approximately $20 billion (based o | 2025-11-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Abbott Laboratories — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.